Description
What is Xeljanz (tofacitinib)?
Xeljanz (tofacitinib) is an inhibitor of Janus kinases (JAKs). It is used to treat moderately to severely active rheumatoid arthritis[1,2,3] active psoriatic arthritis[1], and moderately to severely active ulcerative colitis[1].
Who is it for?
Xeljanz (tofacitinib) is an inhibitor of Janus kinases (JAKs) used to treat adult patients with:
-
- moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate[1,2,3]
- active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs)[1,2,3].
- moderately to severely active ulcerative colitis[1,2].
How does Xeljanz (tofacitinib) work?
The active substance in Xeljanz, tofacitinib, acts on enzymes known as Janus kinases. These enzymes play an important role in the process of inflammation4 that characterises inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. By blocking their action, tofacitinib helps reduce the inflammation and other symptoms of inflammatory diseases[4].
Where has Xeljanz (tofacitinib) been approved?
Xeljanz (tofacitinib) was approved by:
- Food and Drug Administration (FDA), USA:
- European Medical Agency (EMA), European Union:
- Therapeutic Goods Administration (TGA), Australia:
- Health Canada on June 3, 2014[12]:
- for the treatment of moderate to severely active rheumatoid arthritis
- for the treatment of psoriatic arthritis
- for the treatment of moderate to severely active ulcerative colitis.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Xeljanz (tofacitinib) taken?
The standard dosage is[9]:
- 5 mg twice daily.
Reviews
There are no reviews yet.